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Background. Diabetes mellitus is linked to premature
mortality of virtually all causes. Furin is a propro-
tein convertase broadly involved in the mainte-
nance of cellular homeostasis; however, little is
known about its role in the development of diabetes
mellitus and risk of premature mortality.
Objectives. To test if fasting plasma concentration of
furin is associated with the development of dia-
betes mellitus and mortality.
Methods. Overnight fasted plasma furin levels were
measured at baseline examination in 4678 indi-
viduals from the population-based prospective
Malm€o Diet and Cancer Study. We studied the
relation of plasma furin levels with metabolic and
hemodynamic traits. We used multivariable Cox
proportional hazards models to investigate the
association between baseline plasma furin levels
and incidence of diabetes mellitus and mortality
during 21.3–21.7 years follow-up.
Results. An association was observed between quar-
tiles of furin concentration at baseline and body
mass index, blood pressure and plasma concen-
tration of glucose, insulin, LDL and HDL choles-
terol (|0.11| ≤ b ≤ |0.31|, P < 0.001). Plasma furin
(hazard ratio [HR] per one standard deviation
increment of furin) was predictive of future dia-
betes mellitus (727 events; HR = 1.24, CI = 1.14–
1.36, P < 0.001) after adjustment for age, sex,
body mass index, systolic and diastolic blood
pressure, use of antihypertensive treatment,
alcohol intake and fasting plasma level of glu-
cose, insulin and lipoproteins cholesterol. Furin
was also independently related to the risk of all-
cause mortality (1229 events; HR = 1.12,
CI = 1.05–1.19, P = 0.001) after full multivari-
able adjustment.
Conclusion. Individuals with high plasma furin con-
centration have a pronounced dysmetabolic phe-
notype and elevated risk of diabetes mellitus and
premature mortality.
Keywords: diabetes mellitus, furin, mortality,
population-based cohort, risk prediction.
Introduction
Diabetes mellitus (DM) is associated with risk of
premature mortality from vascular disease, several
cancers and nonvascular causes not attributed to
cancer, including digestive diseases, infectious
diseases and neurological disorders, indepen-
dently of major risk factors [1].
Furin, a type-1membrane-bound protease, belongs
to the proprotein convertase subtilisin/kexin family
(PCSK), which comprises of a total of nine members
[2]. Furin cleaves numerous protein and peptide
precursors trafficking through the secretory path-
way and plays a pivotal role in several physiological
processes [3]. Furin is expressed ubiquitously in all
mammalian tissues and cell lines examined [4], but
the level of expression differs being high in endo-
crine tissues, intermediate in the liver and gas-
trointestinal tract and very low in muscle tissues
(www.proteinatlas.org) [5].
The manuscript has been handled by an external editor, Professor
Sam Schulman, Thrombosis Service, McMaster Clinic, HHS –
General Hospital 237, Barton Street East, Hamilton, ON, L8L
2X2, Canada.
ª 2018 The Authors Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine 377
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License,
which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and
no modifications or adaptations are made.
Original Article
Previous evidence suggests a connection between
furin and metabolic risk. A point mutation at the
insulin pro-receptor processing site, later identified
as a furin cleavage site [6], was reported in an
individual suffering from extreme insulin-resistant
diabetes and resulted in the absence of the pro-
receptor processing [7]. An association between a
polymorphism in the furin gene and decreased
triglycerides and increased high-density lipopro-
tein cholesterol (HDL-C) serum concentration was
recently established [8]. Moreover, in a recent
epidemiological study, elevated circulating furin
levels were demonstrated to be associated with a
score for the metabolic syndrome as well as with
increased BMI and blood triglyceride concentration
[9]. However, there is limited knowledge about the
role of furin in the development of DM and risk of
premature mortality.
In this study, we measured fasting plasma levels of
furin in a large population-based prospective
cohort study from Malm€o, Sweden and related
circulating furin levels to incidence of DM, all-
cause and cause-specific mortality during a long-
term follow-up.
Materials & methods
Study participants and data collection
The Malm€o Diet and Cancer (MDC) study is a
population-based, prospective epidemiologic
cohort consisting of 28 449 individuals who
attended a baseline examination between 1991
and 1994 [10]. From this cohort, 6103 people were
randomly selected and asked to participate in a
cardiovascular cohort (MDC-CC), which was
designed to study the epidemiology of carotid artery
disease [11]. At baseline, all the MDC-CC partici-
pants underwent a medical history, physical exam-
ination and laboratory assessment. Of the MDC-CC
participants, fasting plasma samples were available
in 4678 subjects for analysis of circulating furin.
Participants with plasma samples had similar age
(57.4  5.9 vs. 57.4  5.9; P = 0.98), LDL-C
(4.2  1.0 vs. 4.1  1.0; P = 0.51) and use of anti-
hypertensive therapy (16.5% vs. 16.7%, P = 0.91)
compared to those who lacked plasma (n = 1425).
However, there were some differences between
these two groups in terms of gender (60% women
vs. 50.5%, P < 0.001), BMI (25.7  3.9 vs.
26.3  4.1; P < 0.001), SBP (141.0  18.9 vs.
142.8  19.7; P = 0.002), HDL-C (1.4  0.4 vs.
1.3  0.4; P < 0.001), glucose (5.1  1.3 vs.
5.5  1.8; P < 0.001), prevalent DM (7.6% vs.
9.3%, P < 0.001) and smoking status (26% vs.
27%, P < 0.001).
Systolic (SBP) and diastolic blood pressure (DBP)
were measured using a mercury-column sphyg-
momanometer after 10 min of rest in the supine
position. Data on current smoking, use of anti-
hypertensive treatment and physical activity
during leisure time (PAL) were ascertained from
a baseline questionnaire. Alcohol consumption
was established from a 7-day food diary [12]. PAL
was transformed into a score as previously
described [12]. BMI was calculated as weight in
kilograms divided by the square of the height in
metres.
DM at baseline was defined as a fasting whole
blood glucose ≥6.1 mmol L1 or self-report of a
physician diagnosis or use of diabetes medication.
All participants provided written informed consent,
and the study was approved by the Ethics Com-
mittee at Lund University, Lund, Sweden.
Laboratory measurements
All laboratory assays were performed on overnight
fasted blood samples obtained at the time of the
baseline examination. Analyses of plasma lipids,
insulin and whole blood glucose were performed
according to standard procedures at the Depart-
ment of Clinical Chemistry, Skane University
Hospital in Malm€o. The levels of LDL cholesterol
(LDL-C) were calculated according to the Friede-
wald formula.
Fasting plasma levels of furin were measured,
togetherwith 56 other proteins, usingOlinkProseek
Multiplex proximity extension assay (PEA) at the
Clinical Biomarkers Facility, Science for Life Labo-
ratory, Uppsala, Sweden. PEA uses two highly
specific oligonucleotide labelled antibodies per pro-
tein, which allows the formation of a PCR reporter
sequence when both antibodies are bound to the
target protein’s surface. This sequence is then
quantified by real-time quantitative PCR [13]. A goat
polyclonal furin antibodywas used in the assay that
in direct ELISA has less than 1% cross-reactivity
with any other human protein. The intra and inter-
assay variability for the assay were respectively 5%
and 18% (https://www.olink.com/products/docu
ment-download-center/).Furin levelsweresuccess-
fully measured in all the samples. Data are
presented as arbitrary units (AU).
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Follow-up and end-points retrieval
Subjects were followed for first incidence of DM,
coronary artery disease, as well as all-cause and
cause-specific mortality until the 31st of December
2014. DM was defined as a fasting plasma glucose
of ≥7.0 mmol L1 or a history of physician diagno-
sis of DM or being on diabetes medication or having
been registered in local or national diabetes
registries [14]. Coronary artery disease was
defined as coronary revascularization, fatal or
nonfatal myocardial infarction, or death due to
ischaemic heart disease. Mortality components
were defined on the basis of the International
Classification of disease – 9th revision (ICD-9)
and the ICD-10 as follows: deaths from cancer,
ICD-9 codes 140–239 and ICD-10 codes C00-
D48; death from cardiovascular disease, ICD-9
codes 390–459 and ICD-10 codes I00-I99; death
from other causes, ICD-9 codes 001–139, 240–
389, 460–739 and ICD-10 codes A00-B99, D50-
89, E00-H95, J00-R99, V00-Y99. End-points
were retrieved through record linkage of the
personal identification number of each Swedish
citizen with Swedish local or national registries as
previously described [14, 15].
Statistics
SPSS (version 22.0) was used for all statistical
analyses. Due to non-normality, fasting plasma
concentration of furin, glucose and insulin were
transformed with the natural logarithm. All con-
tinuous variables were scaled to multiples of one
standard deviation (SD) and centred on zero prior
to statistical analysis.
Cross-sectional analyses were performed at base-
line using linear regression models adjusting for
age and sex with quartiles of furin levels as the
independent variable and the respective standard-
ized clinical parameter as dependent variable (i.e.
BMI, fasting plasma concentrations of glucose,
insulin, LDL-C and HDL-C, SBP, DBP, alcohol
intake). The Pearson chi-square test was used to
study the association between quartiles of baseline
plasma furin concentration and the dichotomous
categorical variables, gender, antihypertensive
treatment, smoking status and physical activity
score.
Kaplan–Meier survival curve was used to describe
the rate of primary DM and all-cause of mortality
outcome over time in quartiles of baseline furin
levels. Multivariable Cox proportional hazards
models were adopted to examine the association
between fasting plasma levels of furin and each of
the outcomes after removal of the prevalent cases
for the specific end-point. Of the 4678 partici-
pants in whom furin was measured, those without
complete data on covariates were excluded from
the analyses. Hazard ratios (HRs) for furin were
expressed per 1-SD increment of the natural
logarithm of furin or per increasing quartiles of
furin (quartiles 2 through 4 compared with quar-
tile 1).
In analyses of incident DM, we adjusted in model 1
for age and sex and in model 2 for all the covariates
demonstrating a statistically significant associa-
tion with furin in the aforementioned cross-sec-
tional analyses, which are presented in Table 1 (i.e.
age, sex, BMI, SBP, DBP, use of antihypertensive
treatment, alcohol intake and fasting plasma con-
centrations of glucose, insulin, LDL-C and HDL-C
at baseline examination). In analyses of all-cause
and cause-specific mortality and coronary artery
disease incidence, we adjusted in model 1 for age
and sex and in model 2 for all the cardiometabolic
risk factors demonstrating an association with
furin in Table 1 (i.e. age, sex, BMI, SBP, DBP, use
of antihypertensive treatment, prevalent DM, alco-
hol intake and fasting plasma levels of LDL-C and
HDL-C at baseline).
Tests for interactions were performed by including
prevalent DM, standardized furin levels, and their
multiplicative factor adjusting for age, sex, BMI,
SBP, DBP, use of antihypertensive treatment,
alcohol intake and fasting plasma levels of LDL-C
and HDL-C at baseline.
A 2-sided P value of <0.05 was considered statis-
tically significant.
Results
Association between plasma furin levels and clinical parameters
The baseline characteristics of the study partici-
pants are listed in Table 1. The fasting levels of
plasma furin at baseline examination were associ-
ated significantly and very strongly with all meta-
bolic (BMI, plasma concentrations of glucose,
insulin, LDL-C and HDL-C) (|0.11| ≤ b ≤ |0.31|,
P < 0.001) and hemodynamic (SBP, DBP, antihy-
pertensive treatment) (b = 0.15, P < 0.001) traits
investigated. Participants in the lowest quartile of
furin were younger, leaner, had lower levels of
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fasting circulating glucose and insulin, a more
favourable lipid profile and lower blood pressure
compared with participants in the highest quartile
of furin (Table 1).
Furin levels were elevated in the participants with
DM at baseline (n = 187) compared to those with-
out diabetes (n = 4491) (6.65 arbitrary units
(AU)  0.5 vs. 6.46 (AU)  0.5 and P < 0.001).












(n = 1169) b (SE) or v2 (df) Pa
Age (years) 55.71  5.88 57.38  5.78 58.19  5.91 58.63  5.80 0.96  0.08 <0.001
Sex, No.
(% women)
752 (64.3) 658 (56.2) 712 (60.9) 686 (58.7) 17.22 (3) 0.001
















1.51  0.38 1.41  0.37 1.38  0.37 1.27  0.33 0.20  0.01 <0.001
SBP (mm Hg) 135.37  17.99 138.56  17.75 143.41  19.16 146.60  18.68 0.15  0.01 <0.001




117 (10) 163 (13.9) 220 (18.8) 274 (23.4) 86.52 (3) <0.001




28 (2.4) 44 (3.8) 38 (3.2) 77 (6.6) 30.13 (3) <0.001
Alcohol
intake (g day1)




269 (24.4) 258 (23.8) 276 (25.9) 268 (25.6) 1.72 (3) 0.63
Values are displayed as mean  SD, median and 25–75% interquartile range, or frequency in per cent.
b coefficients represent the standardized change of a clinical parameter per quartile of furin.
AU, arbitrary units; DBP, diastolic blood pressure; HDL-C, HDL cholesterol; LDL-C, LDL cholesterol; SBP, systolic blood
pressure.
aP values were obtained from linear regressions adjusted for age and sex for the continuous variables or from Pearson chi-
square tests for the binary variables. bPhysical activity was defined as the top quartile (i.e. coded 1) versus the lowest three
quartiles (i.e., coded 0) of the physical activity score.
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Furin and risk of diabetes mellitus
Amongst 4490 participants free from DM at base-
line examination, 750 developed new-onset DM
during a median follow-up time of 21.3 years
[25–75% interquartile range (IQR) 16.2–22.3]. The
cumulative incidence rate of DM according to
quartiles of baseline fasting plasma concentration
of furin was higher for subjects in the upper
quartiles (Fig. 1). A higher fasting value of furin
(HR/SD increment of natural logarithm of fasting
furin) was associated with increased risk of DM
after age and sex adjustment (model 1) (HR = 1.82,
CI = 1.68–1.96, P < 0.001) (Table 2). The associa-
tion remained significant after further adjustment
for BMI, SBP, DBP, use of antihypertensive treat-
ment, alcohol intake and fasting plasma levels of
glucose, insulin, LDL-C and HDL-C at baseline
(model 2), with a multivariable-adjusted HR of 1.24
(95% CI, 1.14–1.36, P < 0.001) per one SD incre-
ment of furin for risk of future DM (Table 2). There
was a linear relationship between plasma furin
concentration and the risk of incident DM in both
model 1 and 2 (P for trend < 0.001), and the top
versus bottom quartile of furin in the fully adjusted
model was associated with a HR of 1.72 (95% CI,
1.33–2.23) (Table 2).
Furin and risk of all-cause mortality
A total of 1263 participants died during a median
follow-up time of 21.7 years [IQR, 20.9–22.4]. The
cumulative incidence rate of all-cause mortality in
quartiles of baseline fasting plasma concentration
of furin is presented in Fig. 2 and was higher for
participants with high plasma concentration of
furin. Increasing furin levels associated signifi-
cantly with elevated all-cause mortality during
follow-up after age and sex adjustment (model 1)
(P < 0.001) (Table 3). After further adjustment for
BMI, SBP, DBP, use of antihypertensive treatment,
alcohol intake, prevalent diabetes mellitus and
fasting plasma concentrations of LDL-C and HDL-
C at baseline (model 2), the association remained
significant (P = 0.001). Each one SD increase of
baseline furin was associated with a multivariable-
adjusted HR of 1.12 (95% CI, 1.05–1.19) and top
versus bottom quartile of furin was associated with
a HR of 1.37 (95% CI, 1.14–1.64, P for trend
<0.001) for risk of all-cause mortality (Table 3).
Fig. 1 Association between
baseline furin levels and
incidence of diabetes mellitus
in the MDC-CC. The Kaplan–
Meier plot shows cumulative
percentages of diabetes
mellitus events during follow-
up according to the quartiles of
fasting plasma furin levels at
baseline examination (Q1;
lowest and Q4; highest). The
numbers at risk are shown at
5-year intervals.
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Furin and risk of cause-specific mortality
In the next step, we investigated how plasma furin
levels relate to the main causes of death. After
adjustment for baseline age and sex (model 1),
each SD increment of furin was associated with
HRs of 1.14 (95% CI, 1.04–1.24) for death from
cancer, 1.31 (95% CI, 1.17–1.46) for death from
cardiovascular causes and 1.13 (95% CI, 1.01–
1.26) for death from noncardiovascular causes not
attributed to cancer (Table 3). However, furin levels
did not associate with total cancer incidence in an
age and sex-adjusted model (1210 events; HR,
1.04; 95% CI, 0.98–1.10; P = 0.25).
These HRs were reduced after full adjustment for
conventional risk factors for cardiovascular dis-
ease that is age, sex, BMI, SBP, DBP, use of
antihypertensive treatment, alcohol intake, preva-
lent diabetes mellitus and fasting plasma concen-
trations of LDL-C and HDL-C at baseline (model 2).
In the fully adjusted models, furin levels only
remained significantly associated with cancer
mortality (HR = 1.13, 95% CI, 1.03–1.25,
P = 0.013) (Table 3). In a next step, we explored
whether plasma furin levels were associated with
coronary artery disease incidence (545 events
during a median follow-up time of 21.4 years
[IQR, 18.6–22.3]). Each SD increment of furin
was associated with a HR of 1.28 (95% CI, 1.17–
1.40; P < 0.001) for the risk of future coronary
artery disease adjusting for age and sex. However,
after full adjustment for the conventional cardio-
vascular disease risk factors, this association was
not statistically significant (530 events; HR, 1.10;
95% CI, 1.00–1.22; P = 0.05).
As furin levels were higher in the participants with
DM at baseline examination, we tested if the
aforementioned associations were dependent on
the DM status at baseline. There was a significant
interaction between prevalence of DM and furin
levels on the outcomes of all-cause mortality,
cardiovascular death and coronary artery disease
(Pinteraction = 0.033, 0.007 and 0.008, respectively)
but not for death from cancer and noncardiovas-
cular noncancer cause (Pinteraction = 0.49 and 0.71,
respectively). Stratifying for DM status at baseline
showed that the positive association between furin
and coronary artery disease remained significant
after full adjustment in participants without DM
despite a smaller sample size (Table 4) but not in
subjects with DM at baseline (Table S1). Further-
more, the association between furin and cardio-
vascular mortality was strengthened in the fully
adjusted model in participants without diabetes
and reached statistical significance.
Discussion
To our knowledge, this is the first epidemiological
study on fasting plasma concentration of furin in
relation to risk of future DM and mortality. We here
show that higher fasting plasma levels of furin in a
middle-aged population were associated with
increased incidence of DM as well as all-cause and
cause-specific mortality during long-term follow-up.
Although furin is a membrane protein, earlier work
indicates the existence of a secreted form of furin. It
has been previously shown that cells transfected
with a recombinant furin gene secrete a soluble
truncated furin protein with similar enzymatic
activity as the membrane-bound protein [16]. Fur-
thermore, it is established that furin is partially
shed from most cells [17]. Plasma furin concentra-
tion has also recently been measured in healthy
Table 2 Incidence of diabetes mellitus in relation to baseline








HRc 1.82 (1.68–1.96) 1.24 (1.14–1.36)
P-value <0.001 <0.001
Quartiles
HRd Q1 1.0 (referent) 1.0 (referent)
HRd Q2 1.50 (1.15–1.96) 1.21 (0.93–1.58)
HRd Q3 2.49 (1.95–3.18) 1.56 (1.21–2.02)
HRd Q4 4.38 (3.47–5.54) 1.72 (1.33–2.23)
P for trende <0.001 <0.001
aModel 1 was adjusted for age and sex. bModel 2 was
adjusted for age, sex, BMI, systolic blood pressure,
diastolic blood pressure, use of antihypertensive treat-
ment, alcohol intake and fasting plasma levels of glucose,
insulin, LDL cholesterol and HDL cholesterol at baseline.
In model 2, individuals without complete data on covari-
ates were excluded from the analysis. cHazard Ratios (HR)
are expressed per 1-SD increment of log-transformed
furin. 95% confidence intervals of the HRs are reported in
parenthesis. dHazard Ratios (HR) are expressed as cate-
gories of furin quartiles using quartile 1 as reference. 95%
confidence intervals of the HRs are reported in parenthe-
sis. eP for trend across quartiles of furin in a linear
regression model.
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individuals in two small studies [9, 18]. Here, we
were able to measure furin levels in the circulation
in a large number of individuals from a middle-
aged general population.
Consistent with our results, in a recent study of
138 participants from the V€asterbotten Interven-
tion Programme, a positive association between
plasma furin levels and BMI was established [9].
We also identified a positive association between
plasma furin levels and plasma concentrations of
glucose, insulin and LDL-C and a negative associ-
ation with HDL-C. The association between circu-
lating furin and LDL-C could be mediated via
PCSK9, as hepatic membrane-bound furin has
been established as the key inactivating protease
of PCSK9 [19]. We also showed a positive associ-
ation between furin levels and both SBP and DBP,
in line with previous findings showing an associa-
tion between polymorphisms in the furin gene and
blood pressure [20, 21].
A key finding of our study was that plasma furin
levels associated with future DM independently of
all traditional DM risk factors. Regarding potential
mechanisms, as furin is responsible for the matu-
ration of the insulin pro-receptor [6], one could
speculate that more furin in the circulation reflects
a compensatory mechanism to increase the syn-
thesis of active insulin receptors. Another possible
mechanism of action of furin in DM development
may be via pancreatic b-cells as furin has been
demonstrated to control the proliferation and dif-
ferentiation of pancreatic b-cell lines and to be
involved in the maturation of insulin secretory
granules [22, 23].
We identified an elevation of furin several years
before the onset of DM. Furthermore, furin levels
remained elevated in overt DM, which is in agree-
ment with a recent study where patients with DM
had a tendency to higher furin plasma levels
compared to healthy subjects [18]. Furthermore,
the aforementioned study established that a strong
increase in plasma furin concentration occurred in
patients with both overt DM and cardiovascular
disease compared to controls.
Because DM predicts premature mortality of virtu-
ally all causes [1], we tested in a next step if
Fig. 2 Association between
baseline furin levels and all-
cause mortality in the MDC-CC.
The Kaplan–Meier plot shows
the survival rate during follow-
up according to the quartiles of
fasting plasma furin levels at
baseline examination (Q1;
lowest and Q4; highest).
Follow-up time is displayed at
5-year intervals.
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baseline plasma furin levels relate to death from
any cause. Participants with elevated furin levels at
baseline were observed to be at higher risk of death
compared to individuals with lower furin levels.
Furthermore, the association between circulating
furin and total mortality was independent of con-
ventional cardiovascular disease risk factors. This
suggests that high fasting furin concentration is
part of a prediabetic phenotype with high risk of
premature mortality.
It is known from previous studies that furin is
linked to the cardiovascular system. For instance,
inactivation of the furin gene in mouse results in
embryonic lethality and failure of the heart tube to
fuse and undergo looping morphogenesis [24].
Furin has also been shown to be involved in human
atherosclerosis as indicated by the increase of furin
mRNA levels in atherosclerotic plaques [25]. More-
over, a recent study identified a genetic association
between a polymorphism in the furin gene and risk
of coronary artery disease [26]. We now took those
findings further and identified a positive associa-
tion between plasma furin levels and cardiovascu-
lar mortality and coronary artery disease. We could
also show that the association between furin levels
and cardiovascular mortality and coronary artery
disease is dependent upon the DM status of the
participants. Furthermore, part of the relationship
between plasma furin levels and cardiovascular
mortality and coronary artery disease could be
mediated through other risk factors for cardiovas-
cular disease and/or confounded by these, as the
associations were weakened after full adjustment
for these risk factors, which in turn were all
strongly correlated with furin levels.
Although it is also known that furin promotes
many cancer-related processes including cell pro-
liferation, migration and invasion [2, 27], we did
not find an association with total cancer incidence.
However, we report in the present study for the first
time that increased plasma furin levels in a middle-
aged cohort are associated with elevated cancer
mortality during long-term follow-up. Furin0s role
is pluripotent [3], which is also demonstrated by
the fact that aside death from cancer and cardiovas-
cular cause, we also observed a positive association
of furin levels with death from noncardiovascular
conditions not attributed to cancer. However, espe-
cially noncardiovascular noncancer mortality is a
heterogeneous group of causes of death, many of
which could in fact be influencedbyCVDandcancer.
Our study has some limitations that deserve clar-
ification. First, we do not have information on
Table 4 Incidence of cardiovascular disease-related mortality and of coronary artery disease in relation to baseline levels of
furin in participants without diabetes
Cardiovascular
death (n = 301/3987)
Model 1a
Cardiovascular
death (n = 293/3940)
Model 2b
Coronary artery
disease (n = 459/3780)
Model 1a
Coronary artery
disease (n = 447/3737)
Model 2b
Overall
HRc 1.31 (1.16–1.48) 1.19 (1.04–1.37) 1.28 (1.16–1.42) 1.17 (1.05–1.30)
P-value <0.001 0.011 <0.001 0.005
Quartiles
HRd Q1 1.0 (referent) 1.0 (referent) 1.0 (referent) 1.0 (referent)
HRd Q2 1.04 (0.71–1.52) 0.99 (0.67–1.45) 1.40 (1.06–1.86) 1.32 (0.99–1.76)
HRd Q3 1.81 (1.29–2.55) 1.55 (1.09–2.21) 1.55 (1.17–2.06) 1.31 (0.98–1.76)
HRd Q4 1.74 (1.23–2.47) 1.40 (0.96–2.04) 1.91 (1.45–2.53) 1.49 (1.10–2.01)
P for trende <0.001 0.015 <0.001 0.018
aModel 1 was adjusted for age and sex. bModel 2 was adjusted for: age, sex, BMI, systolic blood pressure, diastolic blood
pressure, use of antihypertensive treatment, alcohol intake and fasting plasma concentrations of LDL cholesterol and
HDL cholesterol at baseline. In model 2, individuals without complete data on covariates were excluded from the analysis.
cHazard Ratios (HR) are expressed per 1-SD increment of log-transformed furin. 95% confidence intervals of the HRs are
reported in parenthesis. dHazard Ratios (HR) are expressed as categories of furin quartiles using quartile 1 as reference.
95% confidence intervals of the HRs are reported in parenthesis. eP for trend across quartiles of furin in a linear regression
model.
Furin and risk of diabetes and death / C. Fernandez et al.
ª 2018 The Authors Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine 385
Journal of Internal Medicine, 2018, 284; 377–387
whether DM is of type I or II in our cohort. However,
we have assumed that the number of incident type I
DM cases is extremely low, given the participants0
mean age of 57.4  5.9 years at the baseline exam-
ination. Second, furin has been involved in autoim-
munity [28] but we do not have any data regarding
the autoimmunity status in our cohort. Therefore,
we cannot study if autoimmunity contributes to the
premature mortality associated with high furin nor
if there is an autoimmune-related pathogenesis in
the association between high furin levels and DM
incidence. Third, we acknowledge that the sample
size is low for some of the end-points. Fourth, our
cohort may not be fully representative of the back-
ground population as we were lacking some sam-
ples. However, the missing participants only had a
rather modestly more unfavourable metabolic pro-
file than the included participants. Our study also
has some strengths. First, our study had an exten-
sive follow-up of individuals through registers with
no loss of follow-up. Second, selection bias may be a
minor issue considering the population-based
prospective design of our study, which also allowed
us to study several end-points.
In conclusion, individuals with high plasma furin
concentration have a pronounced dysmetabolic
phenotype and elevated risk of diabetes mellitus
and premature mortality. Further mechanistic
studies are now warranted.
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